

A2 desferrioxamine (DFO); parathyroid hormone; anti-microbials, including, but not limited to anti-fungal agents; or any combination thereof.

**IN THE CLAIMS:**

Cancel claims 1-19 without prejudice.

Add claims 20-46 reading as follows:

20. A pharmacological composition comprising:

- (A) at least one biologically-active agent; and  
(B) at least one carrier compound having the formula



or a salt thereof

wherein Ar is a substituted phenyl or naphthyl;

6-170208 R<sup>7</sup> is selected from the group consisting of C<sub>4</sub> to C<sub>20</sub> alkyl, C<sub>4</sub> to C<sub>20</sub> alkenyl, phenyl, naphthyl, (C<sub>1</sub> to C<sub>10</sub> alkyl)phenyl, (C<sub>1</sub> to C<sub>10</sub> alkenyl)phenyl, (C<sub>1</sub> to C<sub>10</sub> alkyl)naphthyl, (C<sub>1</sub> to C<sub>10</sub> alkenyl) naphthyl, phenyl (C<sub>1</sub> to C<sub>10</sub> alkyl), phenyl (C<sub>1</sub> to C<sub>10</sub> alkenyl), naphthyl (C<sub>1</sub> to C<sub>10</sub> alkyl) and naphthyl (C<sub>1</sub> to C<sub>10</sub> alkenyl);

R<sup>7</sup> is optionally substituted with C<sub>1</sub> to C<sub>4</sub> alkyl, C<sub>1</sub> to C<sub>4</sub> alkenyl, C<sub>1</sub> to C<sub>4</sub> alkoxy, -OH, -SH and -CO<sub>2</sub>R<sup>9</sup> or any combination thereof;

R<sup>7</sup> is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

R<sup>8</sup> is selected from the group consisting of hydrogen, C<sub>1</sub> to C<sub>4</sub> alkyl, C<sub>1</sub> to C<sub>4</sub> alkenyl, hydroxy, and C<sub>1</sub> to C<sub>4</sub> alkoxy; and

R<sup>9</sup> is hydrogen, C<sub>1</sub> to C<sub>4</sub> alkyl, or C<sub>1</sub> to C<sub>4</sub> alkenyl;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group.

~~21.~~ The composition of claim 20, wherein Ar is substituted with at least one of C<sub>1</sub>-C<sub>5</sub> alkyl, C<sub>2</sub>-C<sub>4</sub> alkenyl, -F, -Cl, -OH, -SO<sub>2</sub>, -COOH or -SO<sub>3</sub>H.

~~22.~~ The composition of claim 21 wherein Ar is a substituted phenyl.

~~23.~~ The composition of claim 21, wherein Ar is a phenyl substituted with -Cl.

~~24.~~ The composition of claim 21, wherein Ar is a phenyl substituted with -F.

~~25.~~ The composition of claim 23, wherein R<sup>7</sup> is selected from the group consisting of C<sub>4</sub> to C<sub>20</sub> alkyl, (C<sub>1</sub>-C<sub>10</sub> alkyl)phenyl, and phenyl (C<sub>1</sub> to C<sub>10</sub> alkyl).

~~26.~~ The composition of claim 23, wherein R<sup>7</sup> is C<sub>4</sub>-C<sub>20</sub> alkyl.

~~27.~~ The composition of claim 26, wherein R<sup>7</sup> is not substituted or interrupted.

~~28.~~ The composition of claim 27, wherein R<sup>8</sup> is hydrogen.

132 <sup>566</sup> 29. ~~The composition of claim 20, wherein the biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.~~

10 <sup>30</sup> 30. The composition of claim 29, wherein the biologically active agent is a peptide.

11 <sup>31</sup> 31. The composition of claim 29, wherein the biologically active agent is a mucopolysaccharide.

133 <sup>566</sup> 32. ~~The composition according to claim 20, wherein the biologically active agent comprises human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, desferrioxamine, parathyroid hormone, an antimicrobial, an antifungal agent or a combination thereof.~~

13 <sup>33</sup> 33. The composition according to claim 32, wherein said biologically-active agent comprises human growth hormone, an interferon, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, cromolyn sodium, parathyroid hormone, an antimicrobial or a combination thereof.

14 ~~34.~~ The composition according to claim 33, wherein said biologically-active agent comprises human growth hormone.

15 ~~35.~~ The composition according to claim 33, wherein said biologically-active agent comprises insulin.

16 ~~36.~~ The composition according to claim 33, wherein said biologically-active agent comprises heparin.

17 ~~37.~~ The composition according to claim 33, wherein said biologically-active agent comprises low molecular weight heparin.

18 ~~38.~~ The composition according to claim 33, wherein said biologically-active agent comprises calcitonin.

19 ~~39.~~ The composition according to claim 33, wherein said biologically-active agent comprises cromolyn sodium.

20 ~~40.~~ The composition according to claim 33, wherein said biologically-active agent comprises parathyroid hormone.

21 ~~41.~~ A dosage unit form comprising

B4  
Cost

- (A) a pharmacological composition according to claim 20; and
- (B) (i) an excipient,  
(ii) a diluent  
(iii) a disintegrant  
(iv) a lubricant,  
(v) a plasticizer  
(vi) a colorant  
(vii) a dosing vehicle, or  
(viii) any combination thereof..

22  
42.

A dosage unit form according to claim 41, comprising a tablet, a capsule, or a liquid.

23  
43.

A dosage unit form according to claim 41, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol, and any combination thereof.

135  
Sub

44. A method for preparing a pharmacological composition, said method comprising mixing:

- (A) at least one biologically-active agent;  
(B) at least one carrier compound having the formula



6-17-028  
135  
100  
AB  
TOGETHER  
wherein Ar is a substituted phenyl or naphthyl;

R<sup>7</sup> is selected <sup>from</sup> ~~from~~ the group consisting of C<sub>4</sub> to C<sub>20</sub> alkyl, C<sub>4</sub> to C<sub>20</sub> alkenyl, phenyl, naphthyl, (C<sub>1</sub> to C<sub>10</sub> alkyl)phenyl, (C<sub>1</sub> to C<sub>10</sub> alkenyl)phenyl, (C<sub>1</sub> to C<sub>10</sub> alkyl)naphthyl, (C<sub>1</sub> to C<sub>10</sub> alkenyl) naphthyl, phenyl (C<sub>1</sub> to C<sub>10</sub> alkyl), phenyl (C<sub>1</sub> to C<sub>10</sub> alkenyl), naphthyl (C<sub>1</sub> to C<sub>10</sub> alkyl) and naphthyl (C<sub>1</sub> to C<sub>10</sub> alkenyl);

R<sup>7</sup> is optionally substituted with C<sub>1</sub> to C<sub>4</sub> alkyl, C<sub>1</sub> to C<sub>4</sub> alkenyl, C<sub>1</sub> to C<sub>4</sub> alkoxy, -OH, -SH and -CO<sub>2</sub>R<sup>9</sup> or any combination thereof;

R<sup>7</sup> is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

R<sup>8</sup> is selected from the group consisting of hydrogen, C<sub>1</sub> to C<sub>4</sub> alkyl, C<sub>1</sub> to C<sub>4</sub> alkenyl, hydroxy, and C<sub>1</sub> to C<sub>4</sub> alkoxy; and

R<sup>9</sup> is hydrogen, C<sub>1</sub> to C<sub>4</sub> alkyl, or C<sub>1</sub> to C<sub>4</sub> alkenyl;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group; and

(C) optionally a dosing vehicle.

45. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 20.

46. A method for administering a biologically-active agent to a mammal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 20.